NCT06776588Recruiting
Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 18 Nov 2024
- Start date
- 15 Jan 2025
- Primary completion date
- 15 Jan 2028
- Lead sponsor
- Beidahuang Industry Group General Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06776588
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 15 Jan 2025 to the primary completion date, 15 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
Other illness
- Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
- Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
- Patients with severe heart, liver, kidney and brain dysfunction
Lab values
- Platelets \<50×109 /L
Other
- Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
- Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term
- Patients with an estimated survival period of less than 6 months
Who the study is looking for
- Age ≤ 75 years;
- GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
- Refusing radical surgery or being unable to tolerate surgical treatment;
- Normal coagulation function, platelet count ≥ 60 × 109 /L;
- ECOG score ≤ 2 points;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beidahuang Industry Group General Hospital Coordinator of this site? Confirm its status | Harbin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.